
GLP-1 Drugs May Reduce Heavy Drinking, but Evidence on Cravings Remains Mixed
A new review in Biological Psychiatry suggests that GLP-1 receptor agonists, such as semaglutide, may help reduce heavy drinking days and overall alcohol intake for some individuals. However, the evidence is inconsistent regarding whether these drugs effectively reduce alcohol cravings. While clinical trials show promising results for reducing consumption, particularly in people with obesity, the data does not yet confirm a direct link to reduced cravings or establish the drugs as a standard treatment for alcohol use disorder.













